旱地小麦根际细菌中产生1-氨基环丙烷-1-羧酸(ACC)脱氨酶菌株的分离和鉴定

采用富集定向筛选法,从旱地小麦的根际土壤中分离到2株产生1-氨基环丙烷-1-羧酸(ACC)脱氨酶的菌株AS和CS。经测定菌株AS和CS的ACC脱氨酶的比活力分别为0.018 6 U/mg和0.016 7 U/mg蛋白。根据培养特征观察和生理生化指标测定结果,结合16S rDNA碱基序列测定和系统发育同源性分析,确定菌株AS和菌株CS分别属于霍氏肠杆菌(Enterobacter hormaechei)和变形斑沙雷氏菌(Serratia proteamaculans)。     

亚硝基胍诱变选育低温β-半乳糖苷酶高产菌

以野生低温β-半乳糖苷酶产生菌水生拉恩菌(Rahnella aquatilis)14-1为出发菌株.通过亚硝基胍(NTG)诱变及低温驯化,采用选择性平板初筛和摇瓶复筛,筛选出一株产酶活力比原始菌株提高54%的突变株,该突变株经传5代培养,产酶特性稳定.     

(3R)-2-羧乙基-3-氰基-5-甲基己酸乙酯水解酶产生菌的筛选与产酶条件优化

以2-羧乙基-3-氰基-5-甲基己酸乙酯为唯一碳源,采用手性气相法检测,筛选到一株能产对映选择性水解酶的假单胞菌Pseudomonas CGMCC No.4184.该菌产的水解酶能优先水解R型底物产生(3R)-2-羧乙基-3-氰基-5-甲基己酸,产物对映体过量值达到90%以上.对菌株Pseudomonas CGMCC ...     

一株链霉菌21-1的分离鉴定及其对禾谷镰刀菌的抑菌活性

【背景】由禾谷镰刀菌(Fusarium graminearum)引起的小麦赤霉病严重威胁我国的小麦生产。【目的】筛选对禾谷镰刀菌具有拮抗能力的链霉菌菌株,为生防菌剂开发提供理论基础。【方法】利用平板对峙法筛选对禾谷镰刀菌具有拮抗能力的链霉菌;通过形态特征、生理生化特征和16S rRNA基因序列分析对其进行鉴定;通过病原菌菌丝生长、孢子产生及萌发抑制试验分析其发酵液的抑菌活性;利用人工接种试验测定该菌株发酵液的防病效果。【结果】筛选到一株对禾谷镰刀菌具有较强拮抗活性的链霉菌21-1,抑菌率为59.5%。依据形态特征、生理生化特性和16S rRNA基因序列分析,将该菌株鉴定为黄三素链霉菌(Streptomycesflavotricini)。菌株21-1发酵液能够抑制禾谷镰刀菌的菌丝生长、孢子产生及萌发过程,而且可以降低禾谷镰刀菌菌丝中可溶性蛋白质的含量,并增加丙二醛的含量。菌株21-1可以产生蛋白酶及纤维素酶。菌株21-1菌液10倍稀释液对小麦赤霉病的防效最佳,为70.1%。此外,菌株21-1发酵液对其他8种植物病原菌均有较好的抑制作用。【结论】菌株21-1对禾谷镰刀菌有较好的抑菌活性,具...     

鼠李糖脂产生菌M7-6在模拟油藏条件下的培养基优化

基于已筛选出的鼠李糖脂产生菌M7-6,在模拟油藏条件(温度、pH、矿化度及缺氧)下,对该菌株的激活剂配方进行了碳源、氮源、碳氮比(C/N)、无机盐等因素的优化,并考察了该菌株在模拟油藏条件下的最佳接种量;利用厌氧发酵罐对菌株M7-6进行了扩大培养,评价菌M7-6的原位代谢活性及与其他微生物类群的竞争作用。结果表明:以甘油为碳源、硝酸盐为氮源、C/N为14.4∶1时,最利于菌株M7-6在模拟油藏条件下生产鼠李糖脂,最小接种量为1%(体积分数)。在厌氧发酵罐中,菌株M7-6可以将培养体系的表面张力降至38.4 mN/m;并且体系中烃降解菌和产酸菌数量有所增加,而硫酸盐还原菌数逐渐减少。     

DL-5-甲基色氨酸的化学合成

<正> DL-5-甲基色氨酸是色氨酸的一种衍生物,它和其它衍生物一起(如DL-5-氟-色氨酸)主要用于处理色氨酸发酵产生菌,从而获得抗类似物高产菌株,在此基础上,利用重组DNA技术,进一步获得“工程菌株”,因此,它是色氨酸发酵科研中的一     

一株人参内生1-氨基环丙烷-1-1羧酸(ACC)脱氨酶活性细菌的筛选、鉴定及其对宿主生长的影响

【目的】从人参内生细菌中获得具有1-氨基环丙烷1-羧酸(ACC)脱氨酶活性的菌株,并进行促生效果的验证。【方法】结合初筛和复筛的方法筛选具有ACC脱氨酶活性的人参内生菌株;采用Ashby培养基和固氮酶基因验证其固氮潜能;菌碟法及钼锑抗比色法测定其解磷能力;CAS方法检测产生铁载体能力;通过室内及田间试验测定菌株对人参生长的促进作用。通过形态学、生理生化测定及16S rRNA序列分析明确菌株的分类地位。【结果】从120株人参内生菌中获得了一株具有较高ACC脱氨酶活性的菌株JJ8-3,其酶活性为α-酮丁酸6.7μmol/(mg·h);且具有解磷特性、固氮潜能和产生铁载体能力;能明显促进人参种子及根部的生长;经鉴定菌株JJ8-3为荧光假单胞菌(Pseudomonas fluorescens)。【结论】获得了一株具有ACC脱氨酶活性的人参内生细菌,将为其在促进植物生长中的应用和研究奠定基础。     

8-甲氧基补骨脂素及其与紫外线复合选育天兰淡红链霉菌的研究

本文比较8-甲氧基补骨脂素(8-Mop)及其与紫外线复合处理柔红霉素产生菌——天兰淡红链霉菌(S．coeruleorubidus)的选育效果,分别获得柔红霉素产率较出发菌株均提高5％以上的高产株,该菌株已在国内应用。     

1株新抑锈病素产生菌FIM03-1149的分离鉴别

在寻找新型抗真菌抗生素的过程中,从海洋放线菌FIM03-1149发酵液中分离到抗真菌抗生素新抑锈病素(Neorustmicin)。菌株FIM03-1149在多数培养基上生长良好,淡黄-橙黄色,无气生菌丝,不产生可溶性色素。形态特征、化学分类特征和生理生化特性等研究表明菌株FIM03-1149属于小单孢菌属。16SrRNA基因序列分析也表明菌株FIM03-1149属于小单孢菌属,但与最接近已知种Micromonospora siamensisTT2-4T处于不同的进化分支,2个菌株在某些生理生化特性上也有不同。基于上述数据,菌株FIM03-1149可能是小单孢菌属的1个新种。     

马铃薯晚疫病菌DK98-1、DX98-2和DX98-3的生物学特性及AFLP指纹分析

利用黑麦培养基和V8-蔬菜汁培养基研究了马铃薯晚疫病菌Phytophthora infestans特异菌株DK98-1、DX98-2和DX98-3的生物学特性,发现该菌株与普通菌株相比菌落生长速度慢、孢子囊产生数量少、有性杂交后卵孢子产生量大(2047～75623个/cm2);利用AFLP分子标记研究这3个菌株的DNA指纹图谱,发现用引物E CG/M CC扩增菌株DK98-1、DX98-2和DX98-3后,在330bp处与普通菌株相比各缺失一条谱带,用引物E AC/M CT扩增菌株DK98-1、DX98-2和DX98-3后,在370bp处比普通菌株增加1条谱带,说明这3个菌株与普通菌株在遗传上明显不同。同时可以利用上述2对特异性引物,鉴定在自然界的晚疫病菌群体中这类特异菌株的出现频率。     

Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism.

The increased energy required for acute moderate exercise by skeletal muscle (SkM) is derived equally from enhanced fatty acid (FA) oxidation and glucose oxidation. Availability of FA also influences contracting SkM metabolic responses. Whole body glucose turnover and SkM glucose metabolic responses were determined in paired dog studies during 1) a 30-min moderate exercise (maximal oxygen consumption of approximately 60%) test vs. a 60-min low-dose 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) infusion, 2) a 150-min AICAR infusion vs. modest elevation of FA induced by a 150-min combined intralipid-heparin (IL/hep) infusion, and 3) an acute exercise test performed with vs. without IL/hep. The exercise responses differed from those observed with AICAR: plasma FA and glycerol rose sharply with exercise, whereas FA fell and glycerol was unchanged with AICAR; glucose turnover and glycolytic flux doubled with exercise but rose only by 50% with AICAR; SkM glucose-6-phosphate rose and glycogen content decreased with exercise, whereas no changes occurred with AICAR. The metabolic responses to AICAR vs. IL/hep differed: glycolytic flux was stimulated by AICAR but suppressed by IL/hep, and no changes in glucose turnover occurred with IL/hep. Glucose turnover responses to exercise were similar in the IL/hep and non-IL/hep, but SkM lactate and glycogen concentrations rose with IL/hep vs. that shown with exercise alone. In conclusion, the metabolic responses to acute exercise are not mimicked by a single dose of AICAR or altered by short-term enhancement of fatty acid supply.     

Total strain fields of the antero-inferior shoulder capsule under subluxation: a stereoradiogrammetric study

The antero-inferior capsule (AIC) is the primary restraint to antero-inferior glenohumeral dislocation. This study utilizes a biomechanical model to determine the total strain field of the AIC in a subluxed shoulder. Strains were calculated from two capsule states: a nominal strain state set by inflation and a strained state set by subluxation. Marker coordinates on the AIC were reconstructed from stereoradiographs and strain fields calculated. Peak strain on the glenoid side of the AIC was significantly greater than the humeral side and strain fields were highly variable. This study reports an accurate method for measuring planar strains in a three-dimensional membrane.     

AICAR Attenuates Organ Injury and Inflammatory Response after Intestinal Ischemia and Reperfusion

Intestinal ischemia and reperfusion (I/R) is encountered in various clinical conditions and contributes to multiorgan failure and mortality as high as 60% to 80%. Intestinal I/R not only injures the intestine, but affects remote organs such as the lung leading to acute lung injury. The development of novel and effective therapies for intestinal I/R are critical for the improvement of patient outcome. AICAR (5-aminoimidazole-4-carboxyamide ribonucleoside) is a cell-permeable compound that has been shown to possess antiinflammatory effects. The objective is to determine that treatment with AICAR attenuates intestinal I/R injury and subsequent acute lung injury (ALI). Male Sprague Dawley rats (275 to 325 g) underwent intestinal I/R injury with blockage of the superior mesenteric artery for 90 min and subsequent reperfusion. At the initiation of reperfusion, vehicle or AICAR (30 mg/kg BW) was given intravenously (IV) for 30 min. At 4 h after reperfusion, blood and tissues were collected for further analyses. Treatment with AICAR significantly decreased the gut damage score and the water content, indicating improvement in histological integrity. The treatment also attenuated tissue injury and proinflammatory cytokines, and reduced bacterial translocation to the gut. AICAR administration after intestinal I/R maintained lung integrity, attenuated neutrophil chemotaxis and infiltration to the lungs and decreased lung levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6. Inflammatory mediators, lung-inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins, were decreased in the lungs and lung apoptosis was significantly reduced after AICAR treatment. These data indicate that AICAR could be developed as an effective and novel therapeutic for intestinal I/R and subsequent ALI.     

13C-enrichment at carbons 8 and 2 of uric acid after 13C-labeled folate dose in man

To evaluate folate-dependent carbon incorporation into the purine ring, we measured (13)C-enrichment independently at C(2) and C(8) of urinary uric acid (the final catabolite of purines) in a healthy male after an independent oral dose of [6RS]-5-[(13)C]-formyltetrahydrofolate ([6RS]-5-H(13)CO-H(4)folate) or 10-H(13)CO-7,8-dihydrofolate (10-H(13)CO-H(2)folate). The C(2) position was (13)C-enriched more than C(8) after [6RS]-5-H(13)CO-H(4)folate, and C(2) was exclusively enriched after 10-H(13)CO-H(2)folate. The enrichment of C(2) was greater from [6RS]-5-H(13)CO-H(4)folate than 10-H(13)CO-H(2)folate using equimolar bioactive doses. Our data suggest that formyl C of [6RS]-10-H(13)CO-H(4)folate was not equally utilized by glycinamide ribotide transformylase (enriches C(8)) and aminoimidazolecarboxamide ribotide (AICAR) transformylase (enriches C(2)), and the formyl C of 10-H(13)CO-H(2)folate was exclusively used by AICAR transformylase. 10-HCO-H(2)folate may function in vivo as the predominant substrate for AICAR transformylase in humans.     

Prior serum- and AICAR-induced AMPK activation in primary human myocytes does not lead to subsequent increase in insulin-stimulated glucose uptake

Exposing isolated rat skeletal muscle to 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside [AICAR, a pharmacological activator of AMP-activated protein kinase (AMPK)] plus serum leads to a subsequent increase in insulin-stimulated glucose transport (Fisher JS, Gao J, Han DH, Holloszy JO, and Nolte LA. Am J Physiol Endocrinol Metab 282: E18-E23, 2002). Our goal was to determine whether preincubation of primary human skeletal muscle cells with human serum and AICAR (Serum+AICAR) would also induce a subsequent elevation in insulin-stimulated glucose uptake. Cells were preincubated for 1 h under 4 conditions: 1) without AICAR or serum (Control), 2) with serum, 3) with AICAR, or 4) with Serum+AICAR. Some cells were then collected for immunoblot analysis to assess phosphorylation of AMPK (pAMPK) and its substrate acetyl-CoA carboxylase (ACC). Other cells were incubated for an additional 4 h without AICAR or serum and then used to measure basal or insulin-stimulated 2-deoxyglucose (2-DG) uptake. Level of pAMPK was increased (P < 0.01) for myotubes exposed to Serum+AICAR vs. all other groups. Phosphorylated ACC (pACC) levels were higher for both Serum+AICAR (P < 0.05) and AICAR (P < 0.05) vs. Control and Serum groups. Basal (P < 0.05) and 1.2 nM insulin-stimulated (P < 0.005) 2-DG uptake was higher for Serum vs. all other preincubation conditions at equal insulin concentration. Regardless of insulin concentration (0, 1.2, or 18 nM), 2-DG was unaltered in cells preincubated with Serum+AICAR vs. Control cells. In contrast to results with isolated rat skeletal muscle, increasing the pAMPK and pACC in human myocytes via preincubation with Serum+AICAR was insufficient to lead to a subsequent enhancement in insulin-stimulated glucose uptake.     

Human AICAR transformylase: role of the 4-carboxamide of AICAR in binding and catalysis

We have prepared 4-substituted analogues of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to investigate the specificity and mechanism of AICAR transformylase (AICAR Tfase). Of the nine analogues of AICAR studied, only one analogue, 5-aminoimidazole-4-thiocarboxamide ribonucleotide, was a substrate, and it was converted to 6-mercaptopurine ribonucleotide. The other analogues either did not bind or were competitive inhibitors, the most potent being 5-amino-4-nitroimidazole ribonucleotide with a K(i) of 0.7 +/- 0.5 microM. The results show that the 4-carboxamide of AICAR is essential for catalysis, and it is proposed to assist in mediating proton transfer, catalyzing the reaction by trapping of the addition compound. AICAR analogues where the nitrogen of the 4-carboxamide was derivatized with a methyl or an allylic group did not bind AICAR Tfase, as determined by pre-steady-state burst kinetics; however, these compounds were potent inhibitors of IMP cyclohydrolase (IMP CHase), a second activity of the bifunctional mammalian enzyme (K(i) = 0.05 +/- 0.02 microM for 4-N-allyl-AlCAR). It is proposed that the conformation of the carboxamide moiety required for binding to AICAR Tfase is different than the conformation required for binding to IMP CHase, which is supported by inhibition studies of purine ribonucleotides. It is shown that 5-formyl-AICAR (FAICAR) is a product inhibitor of AICAR Tfase with K(i) of 0.4 +/- 0.1 microM. We have determined the equilibrium constant of the transformylase reaction to be 0.024 +/- 0.001, showing that the reaction strongly favors AICAR and the 10-formyl-folate cofactor. The coupling of the AICAR Tfase and IMP CHase activities on a single polypeptide allows the overall conversion of AICAR to IMP to be favorable by coupling the unfavorable formation of FAICAR with the highly favorable cyclization reaction. The current kinetic studies have also indicated that the release of FAICAR is the rate-limiting step, under steady-state conditions, in the bifunctional enzyme and channeling is not observed between AICAR Tfase and IMP CHase.